Pneumococcal conjugate second or third-dose vaccines (PCVc) in South Korea
South Korea: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 97.0% in 2025. ◆ Volatile
Latest (2025)
97.0%
Change on year
unchanged
World rank
17th
of 194 countries
All-time high
98.0%
in 2016
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in South Korea, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in South Korea stood at 97.0%.
Compared with earlier readings it is unchanged over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in South Korea peaked at 98.0% in 2016 and was at its lowest, 0.0%, in 2008.
South Korea ranks 17th of 194 countries on this measure, in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in South Korea, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 97.0% | — |
| 2016 | 98.0% | +1.0% |
| 2017 | 97.0% | -1.0% |
| 2018 | 97.0% | +0.0% |
| 2019 | 98.0% | +1.0% |
| 2020 | 97.0% | -1.0% |
| 2021 | 97.0% | +0.0% |
| 2022 | 97.0% | +0.0% |
| 2023 | 97.0% | +0.0% |
| 2024 | 97.0% | +0.0% |
| 2025 | 97.0% | +0.0% |
South Korea compared with similar countries
- South Korea's 97.0% is above the median for high income countries, which is 91.0%, 1.1× the median. (63 countries reporting)
- South Korea's 97.0% is above the median for East Asia & Pacific, which is 81.0%, 1.2× the median. (30 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 48.7% | 0.0% | 98.0% | 10 |
| 2020s | 97.0% | 97.0% | 97.0% | 6 |
Countries ranked near South Korea
More health data for South Korea
- Un projection of annual infant deaths, annual growth rate -1.43 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.1935 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 2,072 deaths per 1,000 people (2090)
- Number of infants who die before age 1 69 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.66 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0118 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.76 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in South Korea?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in South Korea was 97.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in South Korea?
- The highest recorded value was 98.0% in 2016.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in South Korea?
- The lowest recorded value was 0.0% in 2008.
- How does South Korea rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- South Korea ranks 17th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in South Korea?
- Over the last ten years it is unchanged. The long-run trend across the full record is volatile.
- Where does this South Korea data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).